Sovatelitide

Summary

Sovatelitide (CHEMBL3188091) is a phase-3 clinical-stage protein targeting EDNRB; indicated across 5 conditions including stroke disorder and non-small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Targets: 1 (EDNRB)
• Indications: 5 conditions
• Clinical trials: 5
• Chemistry: 1820.9 Da · C86H117N17O27

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3188091
Name	Sovatelitide
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	16133819
Molecular formula	C86H117N17O27
Molecular weight	1820.9
InChIKey	DXPHNGAMYPPTBJ-TZMIJSMNSA-N

SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O

IUPAC name: (4S)-4-[[(2S)-4-carboxy-2-[[(2S)-3-carboxy-2-(3-carboxypropanoylamino)propanoyl]amino]butanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid

Also known as: Irl-1620, IRL-1620, PMZ-1620, Sovatelitide, Sovateltide, SPI 1620, Spi 1620, Spi-1620, SPI-1620, SID50112622, SOVATELITIDE

Patent coverage: 31 distinct patent families (79 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 74 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
EDNRB	ETB receptor	Full agonist	10.1	0%	P24530

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): EDNRB.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Peptide ligand-binding receptors	1	EDNRB
G alpha (q) signalling events	1	EDNRB
Transcriptional and post-translational regulation of MITF-M expression and activity	1	EDNRB

Dominant GO biological processes

GO term	Targets
negative regulation of transcription by RNA polymerase II	1
neural crest cell migration	1
renin secretion into blood stream	1
regulation of heart rate	1
regulation of pH	1
cell surface receptor signaling pathway	1
negative regulation of adenylate cyclase activity	1
phospholipase C-activating G protein-coupled receptor signaling pathway	1
positive regulation of cytosolic calcium ion concentration	1
nervous system development	1
peripheral nervous system development	1
posterior midgut development	1
positive regulation of cell population proliferation	1
gene expression	1
negative regulation of neuron maturation	1

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
stroke disorder	3	MONDO:0005098	EFO:0000712
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
biliary tract neoplasm	2	MONDO:0005304	EFO:0003891
spinal cord injury	2	MONDO:0043797	EFO:1001919
carcinoma	1	MONDO:0004993	EFO:0000313

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	2
PHASE4	1
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05955326	PHASE4	RECRUITING	Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05691244	PHASE3	RECRUITING	Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT01741155	PHASE2	TERMINATED	Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
NCT01773785	PHASE2	TERMINATED	Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
NCT00613691	PHASE1	COMPLETED	A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

27 molecules share ≥1 primary target. Top 27 by shared-target count:

Molecule	Source	Status	Shared targets
BOSENTAN	ChEMBL + PubChem	Phase 4 (approved)	EDNRB
AMBRISENTAN	ChEMBL	Phase 4 (approved)	EDNRB
APROCITENTAN	ChEMBL	Phase 4 (approved)	EDNRB
MACITENTAN	ChEMBL	Phase 4 (approved)	EDNRB
MAZINDOL	ChEMBL	Phase 4 (approved)	EDNRB
MODAFINIL	ChEMBL	Phase 4 (approved)	EDNRB
SITAXENTAN	ChEMBL	Phase 4 (approved)	EDNRB
SULFISOXAZOLE	ChEMBL	Phase 4 (approved)	EDNRB
ATRASENTAN	ChEMBL	Phase 3	EDNRB
AVOSENTAN	ChEMBL	Phase 3	EDNRB
CLAZOSENTAN	ChEMBL	Phase 3	EDNRB
DARUSENTAN	ChEMBL	Phase 3	EDNRB
TEZOSENTAN	ChEMBL	Phase 3	EDNRB
ENDOTHELIN	ChEMBL	Phase 2	EDNRB
ENRASENTAN	ChEMBL	Phase 2	EDNRB
FELOPRENTAN	ChEMBL	Phase 2	EDNRB
Aclidinium Bromide	PubChem	Approved	EDNRB
Alogliptin	PubChem	Approved	EDNRB
Belzutifan	PubChem	Approved	EDNRB
Desloratadine	PubChem	Approved	EDNRB
Dihydroergotamine	PubChem	Approved	EDNRB
Fidaxomicin	PubChem	Approved	EDNRB
Methotrexate	PubChem	Approved	EDNRB
Olmesartan Medoxomil	PubChem	Approved	EDNRB
Propoxyphene	PubChem	Approved	EDNRB
Pyrazinamide	PubChem	Approved	EDNRB
Tiotropium Bromide Monohydrate	PubChem	Approved	EDNRB